GenomeRNAi - a database for RNAi phenotypes and reagents
TitleScreen TitleAssayBiomodelSpecies
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Tyner et al. (2008) Cell viability Cell viabilityCMK, HMC1.1 (white blood cells)H. sapiens


Despite vast improvements in our understanding of cancer genetics, a large percentage of cancer cases present without knowledge of the causative genetic events. Tyrosine kinases are frequently implicated in the pathogenesis of numerous types of cancer, but identification and validation of tyrosine kinase targets in cancer can be a time-consuming process. We report the establishment of an efficient, functional screening assay using RNAi technology to directly assess and compare the effect of individually targeting each member of the tyrosine kinase family. We demonstrate that siRNA screening can identify tyrosine kinase targets containing activating mutations in Janus kinase (JAK) 3 (A572V) in CMK cells and c-KIT (V560G) in HMC1.1 cells. In addition, this assay identifies targets that do not contain mutations, such as JAK1 and the focal adhesion kinases (FAK), that are crucial to the survival of the cancer cells. This technique, with additional development, might eventually offer the potential to match specific therapies with individual patients based on a functional assay.

Screen details

Stable Id: GR00105-A-0
Screen title: Cell viability
Assay: Cell viability
Method: Cell viability (CellTiter 96)
Screen type: Cell-based
Species: Homo sapiens
Biosource: Cell line
Biomodel: CMK, HMC1.1 (white blood cells)
Library: , Dharmacon (tyrosine kinases)
Reagent type: siRNA
Score type: % viability
Cutoff: np